RH5
Phase 2- Indications
- Malaria
Company intelligence / Profile preview
Scala Biodesign has developed a proprietary AI-driven computational protein design platform that enables rapid optimization of proteins for stability, manufacturability, activity, and "humanness" in one step. Their technology has been validated in diverse applications such as improving vaccine candidates' stability and optimizing therapeutic antibodies. The company collaborates with pharmaceutical companies on engineering projects but does not yet have its own clinical pipeline or published human trial results[3][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Scala Biodesign.